PERRIGO Co plcPRGOEarnings & Financial Report
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
PRGO Q4 FY2025 Key Financial Metrics
Revenue
$1.1B
Gross Profit
$362.2M
Operating Profit
$-1.3B
Net Profit
$-1.4B
Gross Margin
32.6%
Operating Margin
-116.0%
Net Margin
-127.8%
YoY Growth
-2.5%
EPS
$-10.23
PERRIGO Co plc Q4 FY2025 Financial Summary
PERRIGO Co plc reported revenue of $1.1B (down 2.5% YoY) for Q4 FY2025, with a net profit of $-1.4B (down 3093.9% YoY) (-127.8% margin). Cost of goods sold was $747.4M, operating expenses totaled $1.6B.
Key Financial Metrics
| Total Revenue | $1.1B |
|---|---|
| Net Profit | $-1.4B |
| Gross Margin | 32.6% |
| Operating Margin | -116.0% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
PERRIGO Co plc Q4 FY2025 revenue of $1.1B breaks down across 5 segments, led by Consumer Self Care Americas at $697.0M (62.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Consumer Self Care Americas | $697.0M | 62.8% |
| Digestive Health | $123.9M | 11.2% |
| Nutrition | $108.3M | 9.8% |
| Healthy Lifestyle | $94.8M | 8.5% |
| Pain And Sleep Aids | $87.1M | 7.8% |
PERRIGO Co plc Revenue by Segment — Quarterly Trend
PERRIGO Co plc revenue by segment across the last 4 reported quarters, showing how each business line (such as Consumer Self Care Americas and Digestive Health) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Consumer Self Care Americas | $697.0M | — | $622.0M | — |
| Digestive Health | $123.9M | $105.5M | — | $103.0M |
| Nutrition | $108.3M | $99.8M | — | $104.8M |
| Healthy Lifestyle | $94.8M | $77.5M | $73.7M | $70.4M |
| Pain And Sleep Aids | $87.1M | $88.6M | $80.2M | $76.6M |
PERRIGO Co plc Annual Revenue by Year
PERRIGO Co plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.3B).
PERRIGO Co plc Quarterly Revenue & Net Profit History
PERRIGO Co plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.1B | -2.5% | $-1.4B | -127.8% |
| Q3 FY2025 | $1.0B | -4.1% | $7.5M | 0.7% |
| Q2 FY2025 | $1.1B | -0.9% | $-8.4M | -0.8% |
| Q1 FY2025 | $1.0B | -3.5% | $-6.4M | -0.6% |
| Q4 FY2024 | $1.1B | — | $-44.4M | -3.9% |
| Q3 FY2024 | $1.1B | -3.2% | $-21.0M | -1.9% |
| Q2 FY2024 | $1.1B | -9.8% | $-108.4M | -10.2% |
| Q1 FY2024 | $1.1B | — | $2.0M | 0.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.08B | $1.07B | $1.09B | $1.14B | $1.04B | $1.06B | $1.04B | $1.11B |
| YoY Growth | N/A | -9.8% | -3.2% | N/A | -3.5% | -0.9% | -4.1% | -2.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.64B | $10.40B | $11.20B | $9.65B | $9.76B | $10.09B | $10.08B | $8.54B |
| Liabilities | $5.95B | $5.85B | $6.64B | $5.33B | $5.40B | $5.62B | $5.64B | $5.60B |
| Equity | $4.69B | $4.55B | $4.57B | $4.32B | $4.36B | $4.47B | $4.45B | $2.94B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.4M | $9.5M | $42.2M | $312.6M | $-64.5M | $75.9M | $51.7M | $175.4M |